A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

Inclusion Criteria: * Body weight \>=40 kg. * Confirmed diagnosis of HbSS (SCD genotype of sickle cell anemia) or HbSβ0 (SCD genotype of sickle cell beta zero thalassemia). * Vaccination against Neisseria Meningitidis serotypes A, C, W, and Y. * Vaccinations against H. influenzae type B and S. pneumoniae. * Participants vaccinated against SARS-CoV-2 are eligible, as long as it has been 3 days or more after inoculation with the vaccine. * Diagnosis of an acute uncomplicated VOE, that requires admission to a hospital/acute medical facility and treatment with parenteral opioid analgesics. * Adequate hepatic and renal function. * Hemoglobin \>=5 grams/deciliter (g/dL) * Platelet count \>=100,000/microliter (µL) * Participants receiving SCD-directed therapies must be on a stable dose for \>=28 days. * For female participants of childbearing potential, an agreement to remain abstinent or use contraception for 322 days (approximately 10.5 months) after the dose of study treatment. Exclusion Criteria: * More than 10 VOEs within the last 12 months prior to presentation, that have required a medical facility visit. * Pain related to the current VOE ongoing for \>36 hours. * Acute pain related to avascular necrosis, hepatic or splenic sequestration, or priapism. * Pain atypical of an acute uncomplicated VOE. * Evidence of or suspicion of ACS. * Evidence or high suspicion of a severe systemic infection. * Major surgery and/or hospitalization for any reason within 30 days. * History of…